Jan Van de Winkel

Jan is President and Chief Executive Officer of Genmab A/S, which he co-founded in Feb 1999. Genmab is a leading international biotechnology company focused on developing innovative antibody products for the potential treatment of cancer. Jan has overseen the creation and development of a number of human antibodies for the treatment of cancer and other life-threatening and debilitating diseases. The first approved antibody, Arzerra, received regulatory authorization by the United States FDA [Oct 2009] and the European Medicines Agency [April 2010] for therapy of refractory chronic lymphocytic leukemia. Jan is widely recognized as one of the leading scientists in the study of antibodies and their interaction with the immune system. He has (co-) authored more than 300 scientific publications and has been responsible for over 40 patents and pending patent applications. He holds a professorship of Immunotherapy at the University Medical Center Utrecht. Prior to joining Genmab, Jan served as Vice President and Scientific Director of Medarex Europe. He is chairman of the board of directors of Regenesance and member of the board of directors of ISA Pharmaceuticals, the scientific advisory board of Thuja Capital Healthcare Fund and the advisory board of Capricorn Health-tech Fund. He holds M.S. and Ph.D. degrees from the University of Nijmegen.